SAN
DIEGO, May 2, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that six data
presentations, including two oral presentations, highlighting the
Company's preclinical gene therapy programs and platforms will be
presented at the American Society of Gene and Cell Therapy (ASGCT)
26th Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually on May 16-20, 2023.
Oral Presentations:
Title: Preclinical Proof-of-Concept: A Novel Hybrid
Gene Therapy Approach to Treat Severe Early-Onset Ornithine
Transcarbamylase Deficiency
Session Title: Metabolic, Storage, Endocrine, Liver and
Gastrointestinal Diseases I
Presentation Time: Thursday, May 18, 2023, 2:30 –
2:45 PM PST
Location: Room 403 AB
Abstract Number: 127
Title: Cas-CLOVER Technology Enables Precise Gene
Editing and Site-Specific Transgene Insertion in Mouse
Liver
Session Title: Gene Targeting and Gene Correction: Liver
Presentation Time: Thursday, May 18, 2023 3:00 –
3:15 PM PST
Location: Room 515 AB
Abstract Number: 157
Poster Presentations:
Title: Demonstration of Human Factor VIII Expression
and Activity Following Single and Repeat Dosing of a Non-Viral
Integrating Gene Therapy
Session Title: Wednesday Poster Session
Session Date/Time: Wednesday, May 17, 2023,
12:00 PM PST
Location: West Hall A
Abstract & Poster Board Number: 638
Title: Development of a Novel Non-Viral Gene Therapy
Platform
Session Title: Thursday Poster Session
Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST
Location: West Hall A
Abstract & Poster Board Number: 945
Title: Editing of a γ-Globin (HBG1/HBG2)
cis-Regulatory Element in Human Hematopoietic Stem and Progenitor
Cells Using Cas-CLOVER™ Technology Reactivates Fetal
Hemoglobin
Session Title: Thursday Poster Session
Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST
Location: West Hall A
Abstract & Poster Board Number: 1212
Title: Development and Optimization of Novel Super
piggyBac®-Based Hybrid Gene Therapy Approach
Session Title: Friday Poster Session
Session Date/Time: Friday, May 19, 2023, 12:00 PM PST
Location: West Hall A
Abstract & Poster Board Number: 1318
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell and gene therapies with the
capacity to cure certain cancers and rare diseases. The Company's
pipeline includes allogeneic CAR-T cell therapy product candidates
for both solid and liquid tumors as well as in vivo gene therapy
product candidates that address patient populations with high unmet
medical need. The Company's approach to cell and gene therapies is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System,
Cas-CLOVER™ Site-Specific Gene Editing System and
nanoparticle and hybrid gene delivery technologies. The Company has
formed global strategic collaborations with Roche and Takeda to
unlock the promise of cell and gene therapies for patients. Learn
more at www.poseida.com and connect with Poseida on Twitter
and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, expected plans with respect to
clinical trials, including timing of regulatory submissions and
approvals and clinical data updates; potential fees, milestones and
other payments that the Company may receive pursuant to its
collaboration agreements; anticipated timelines and milestones with
respect to the Company's development programs and manufacturing
activities and capabilities; the potential capabilities and
benefits of the Company's technology platforms and product
candidates; and the Company's plans and strategy with respect to
developing its technologies and product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the Company's reliance on third parties for various aspects of its
business; risks and uncertainties associated with development and
regulatory approval of novel product candidates in the
biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; the fact that the Company will
have limited control over the efforts and resources that its
strategic partners devote to advancing development programs under
their respective collaboration agreements and the Company may not
receive the potential fees and payments under the collaboration
agreements and the ability of its strategic partners to early
terminate the collaborations, such that the Company may not fully
realize the benefits of such collaborations; and the other risks
described in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-multiple-presentations-at-the-american-society-of-gene-and-cell-therapy-26th-annual-meeting-301813758.html
SOURCE Poseida Therapeutics, Inc.